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of their relatives with schizophrenia were c292 (424), which corresponds to approxi-
mately 14% of the mean gross income of caregivers. Large expenditure items were 
groceries, clothes, rent and travel. CONCLUSIONS: The objective burden adds half-
time to an ordinary fulltime job (time spent on care) and additionally reduces gross 
incomes with approximately 14% (money spent on care) for informal caregivers to 
patients with schizophrenia spectrum disorders. 
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OBJECTIVES: To examine risk of discontinuation of antipsychotics following dis-
charge from acute care settings in Florida for Medicaid-enrolled persons with schizo-
phrenia. METHODS: Medicaid claims, enrollment data, and community services data 
from the state mental health authority from 2004–2008 were used. Demographics, 
diagnosis, service history during the year before admission to acute care (hospitals and 
crisis units), and post-discharge psychopharmacologic treatment were obtained. 
Persons who received antipsychotic monotherapy and had a discharge diagnosis of 
schizophrenia were included. Cox proportional hazards regression estimated risk of 
post-discharge discontinuation of antipsychotics (formulary restrictions were not con-
sidered). Second-generation antipsychotics (SGAs) were examined individually; oral 
ﬁ rst-generation antipsychotics (FGAs) and depot FGAs were each considered as a 
group. Demographics, pre-admission service history, length of stay, and pre-discharge 
length of time receiving medication were control variables. Data were right-censored 
at end of Medicaid enrollment, end of data availability, or death. RESULTS: Partici-
pants (N = 6365) were 42.7 ± 11.2 (mean ± SD) years old; 61% male; 34% white. 
Mean ± SD length of acute care stay was 11.0 ± 19.7 days. Median length of time 
receiving medication post-discharge was 45 days. With risperidone long-acting therapy 
(RLAT) as reference, depot and oral FGAs had highest risk of discontinuation (hazard 
ratio [HR] = 2.49, P < .0001 and HR = 1.68, P = .0005), respectively. Risk was also 
elevated for oral SGAs aripiprazole (HR = 1.65, P = .0012), ziprasidone (HR = 1.46, 
P = .0191), olanzapine (HR = 1.43, P = .0202), and quetiapine (HR = 1.35, P = .0434), 
except for oral risperidone and clozapine. Fewer months receiving pre-discharge 
medication (HR = 1.04, P < .0001), black race (HR = 1.39, P < .0001), history of 
involuntary commitment (HR = 1.28, P < .0001), and more pre-admission acute care 
services (HR = 1.13, P = .0053) were associated with higher risk of discontinuation. 
CONCLUSIONS: Persons with schizophrenia taking oral and depot FGAs were at 
highest risk for discontinuation of medication after discharge from acute care. Those 
taking oral SGAs (except risperidone and clozapine) also may have higher risk of 
discontinuation than patients taking RLAT.
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OBJECTIVES: Non-adherence to antipsychotic therapy can lead to increased risks of 
relapse and rehospitalization. Long-acting injectable antipsychotics have been shown 
to be effective and well-tolerated, with increasing evidence of a potential beneﬁ t on 
adherence. At the time of this study, only one long-acting injectable atypical antipsy-
chotic entity—risperidone—was approved for patients with a diagnosis of schizophre-
nia. The objective of this study was to determine the medication adherence rates of 
Medicaid patients treated with either 1) oral risperidone only, or 2) long-acting inject-
able risperidone +/− oral risperidone. METHODS: Texas Medicaid prescription claims 
data from January 2006 to December 2008 were analyzed for patients with schizo-
phrenia. Records were assessed for a period of 18 months (6-month pre-index period 
with no antipsychotics plus 12-month post-index period). a medication possession 
(MPR) ratio of ≥80% was considered adherent. RESULTS: A total of 1313 patients 
met inclusion criteria, and less than half, 48% (N = 626) had an MPR of at least 80%. 
Of the patients on long-acting injectables +/− oral risperidone, 60% (N = 96/160) were 
adherent with their regimen versus 46% (530/1153) for patients taking only oral 
risperidone. a logistic regression analysis adjusting for demographic covariates 
(gender, race, age) showed that patients on injectable +/− oral medications were about 
80 percent more likely to be adherent (OR = 1.82, 95% CI = 1.29–2.55; p = 0.0006) 
than patients on oral medication alone. There were no statistically signiﬁ cant differ-
ences in any of the demographic characteristics between the two groups. CONCLU-
SIONS: Overall, about half of the patients did not meet the deﬁ nition for medication 
adherence (MPR ≥ 80%) one-year after their index date. Long-acting injectable ris-
peridone had a higher rate of adherence compared to oral risperidone alone. With the 
release of newer atypical long-acting injections (paliperidone and olanzapine), future 
studies comparing adherence rates of these antipsychotic agents are needed.
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OBJECTIVES: Schizophrenia has been found to be associated with poor medication 
compliance, and a higher prevalence of diabetes. Once a hypoglycemic therapy is 
started, appropriate compliance to the therapy is crucial for good glycemic control. 
This study aimed to compare hypoglycemic therapy medication compliance, and 
health care costs after the initiation of the therapy, between type II diabetics with 
schizophrenia versus those without schizophrenia. METHODS: This study used the 
claims database of the National Health Insurance program. Enrollees who began oral 
hypoglycemic therapy in 2001–2002 (the index date), and had been diagnosed with 
schizophrenia and reﬁ lled at least one prescription of antipsychotic(s) in the year prior 
to the index date were included in the study (the case group). Enrollees without 
schizophrenia who began oral hypoglycemic therapy in 2001–2002 were selected from 
a randomly selected sample of the enrollees (the comparison group). Good medication 
compliance was deﬁ ned as an medication possession ratio (MPR) ≥ 0.8. Ordered 
logistic models were adopted to assess associations between factors with medication 
compliance. RESULTS: There were 1196 and 3188 subjects in the case group and 
comparison group, respectively. Forty-one percent of the case group and 30% of the 
comparison group were good compliant. The cost of hypoglycemic therapy was sig-
niﬁ cantly higher in the case group, while the total diabetes-related cost was not sig-
niﬁ cantly different between the two groups. The regression results indicated that 
comorbid schizophrenia was correlated with a higher likelihood of good compliance. 
In a subgroup analysis of diabetics with schizophrenia, good compliance to antipsy-
chotics in the previous year was signiﬁ cantly associated with a greater probability of 
being better compliant with hypoglycemic therapy. CONCLUSIONS: Diabetics with 
schizophrenia, compared with those without such a condition, were more compliant 
in their hypoglycemic therapy, and had higher cost of hypoglycemic therapy in the 
ﬁ rst year of the therapy.
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OBJECTIVES: According to evidence from scientiﬁ c literature the ease of administra-
tion, such as once-daily dosing, improves the adherence and persistance of patients 
with the pharmaceutical therapy. Adherence and persistance are key success factors 
in the treatment of schizophrenic patients, as drug discontinuation or non-adherence 
increase the risk of relapse, which eventually results in reduced quality adjusted life-
years and increased cost of care by more acute hospitalization episodes. Our objective 
was to analyze the impact of once-daily dosing vs. twice daily dosing on the discon-
tinuation rate of pharmaceutical therapy among patients with schizophrenia. 
METHODS: Our real world analysis is based on aggregated data from the Hungarian 
National Health Insurance Fund database. We selected adult patients (between 18–65 
years) on quetiapine therapy with F20 schizoprenia ICD-10 code between January and 
March 2008. We compared the one-year discontinuation rate among once-daily vs. 
twice daily quetiapine users. Discontinuation was deﬁ ned as no prescribed antipsy-
chotic medication in the N05A ATC group between May—July 2009. RESULTS: 
After 1 year 23.4% in the once-daily group compared to 27.2% in the twice-daily 
group discontinued the pharmaceutical therapy. Once-daily dosing reduced the rela-
tive risk of discontinuation by 13.9%. (χ2 test: p = 0,017). The absoluate risk reduction 
was 3.8% (NNT = 26.5). CONCLUSIONS: Our analysis indicates that once-daily 
dosing reduces the risk of drug discontinuation among schizophrenic patients. Short 
time-horizon, potential selection bias and confounding factors may limit the generaliz-
ability of our conclusions. Long-term observational study with multiple regression 
analysis based on anonimized individual patient records can conﬁ rm the validity of 
our ﬁ ndings.
PMH49
ANTIDEPRESSANT UTILIZATION, ADHERENCE AND HEALTH CARE 
SPENDING IN THE UNITED STATES: THE CASE OF MDD PATIENTS 
2000–2007
Lin HC1, Erickson S2, Smith D1, Balkrishnan R2
1University of Michigan, Ann Arbor, MI, USA; 2University of Michigan, 
College of Pharmacy, Ann Arbor, MI, USA
OBJECTIVES: Innovative antidepressants such as SSRIs and SNRIs have been widely 
adopted. However, the differences in patient antidepressant adherence and associated 
health care spending across patient factors and antidepressant choice needed further 
research. This study was trying to understand how patient factors and antidepressant 
choice inﬂ uenced medication adherence and associated health care expenditure. 
METHODS: A retrospective cross-sectional study was conducted using the 2000–
2007 Medical Expenditure Panel Survey (MEPS) database. a multiple OLS regression 
was used to examine MDD patient’s antidepressant adherence measured by propor-
tional days covered (PDC). a two-part model was implemented to study the impact 
of MDD patient factors and antidepressant choice on associated health care expendi-
ture. RESULTS: Linear regression models indicated that patient gender, ethnicity and 
